Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The Washington Post reports.

A federal judge ruled that the policy violated the organization's First Amendment rights. But the Trump administration is likely to appeal the ruling, leaving affiliates unsure of their next move.

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is planning a five-year experiment under which Americans on Medicare and Medicaid could get access to expensive weight loss drugs.